Prenetics Global Limited (PRE)
| Market Cap | 63.44M |
| Revenue (ttm) | 21.74M |
| Net Income (ttm) | -62.72M |
| Shares Out | 12.13M |
| EPS (ttm) | -5.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,323 |
| Open | 5.26 |
| Previous Close | 5.33 |
| Day's Range | 5.16 - 5.66 |
| 52-Week Range | 2.85 - 15.90 |
| Beta | -0.11 |
| Analysts | Buy |
| Price Target | 9.00 (+72.08%) |
| Earnings Date | Jun 3, 2024 |
About PRE
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Glob... [Read more]
Financial Performance
In 2023, PRE's revenue was $21.74 million, an increase of 65.17% compared to the previous year's $13.16 million. Losses were -$62.72 million, -67.07% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PRE stock is "Buy" and the 12-month stock price forecast is $9.0.
News
Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results
HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financ...
Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station
(From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dub...
Prenetics Announces Third Quarter 2023 Financial Results
HONG KONG, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results...
Prenetics Global Limited Announces Reverse Stock Split
HONG KONG, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading-genomics-driven health sciences company today announced that it will proceed with a reverse stock split o...
Prenetics Announces Second Quarter 2023 Financial Results
HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial result...
Prenetics CEO discusses $200 million JV for early cancer detection breakthrough
Danny Yeung, CEO of Hong Kong's genetics testing firm Prenetics, speaks about the $200 million joint venture that his company has formed with professor Dennis Lo from Chinese University of Hong Kong, ...
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening
Company will Host Conference Call to Discuss the Transaction on June 26 at 8:30 a.m. EDT Company will Host Conference Call to Discuss the Transaction on June 26 at 8:30 a.m. EDT
Prenetics Announces First Quarter 2023 Financial Results
HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results...
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results
New Business Strategy Focused on Precision Oncology New Business Strategy Focused on Precision Oncology
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
LONDON and HONG KONG, March 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scien...
Prenetics to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
LONDON and HONG KONG, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that its management team will participate vi...
Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA
LONDON and HONG KONG, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure the ...
Prenetics Global's stock rallies 82%
Shares of Prenetics Global Ltd. PRE, -2.11% jumped about 82% in premarket trading on Tuesday after the company said ActOnco's genomic test for tumors recently received clearance from the Food and Drug...
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
LONDON and HONG KONG, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company which Prenetics ...
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
LONDON and HONG KONG, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that it is acquiring a majority stake in ACT...
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
LONDON and HONG KONG, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced that i...
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
LONDON and HONG KONG, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its un...
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
LONDON and HONG KONG, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its u...
Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker “PRE.”
LONDON and HONG KONG, June 06, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its un...
Prenetics Rings the Opening Bell and Debuts on Nasdaq
LONDON and HONG KONG, May 18, 2022 (GLOBE NEWSWIRE) -- Prenetics Group Limited ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, and Artisan Acquisition Corp. (Nasdaq:...